UK markets closed

AMGN Jul 2024 310.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
3.2500+0.1000 (+3.17%)
As of 10:22AM EDT. Market open.
Full screen
Previous close3.1500
Open2.9800
Bid3.5000
Ask4.4500
Strike310.00
Expiry date2024-07-19
Day's range2.9500 - 3.2500
Contract rangeN/A
Volume4
Open interest648
  • Yahoo Finance Video

    Amgen, DraftKings, Live Nation: Trending tickers

    Shares of Amgen (AMGN) are soaring at Thursday's market close after reporting first quarter results, with revenue exceeding expectations. The biotechnology giant's revenue rose by 22% during the quarter. DraftKings (DKNG) also delivered a strong earnings report, surpassing analysts' estimates on both the top and bottom lines. Buoyed by this performance, the company raised its full-year outlook. Live Nation (LYV) topped revenue estimates in its first quarter earnings, although the company reported a loss of $0.53 per share. For more expert insight and the latest market action, click here to watch this full episode of Market Domination Overtime. This post was written by Angel Smith

  • Reuters

    UPDATE 1-Amgen first-quarter profit dips 1%, revenue rises 22%

    Amgen reported a slightly lower first-quarter profit on Thursday, citing higher operating and interest expense from its recent acquisition of rare disease drugmaker Horizon Therapeutics, partially offset by double-digit revenue growth. The biotechnology company's adjusted profit fell 1% to $3.96 per share, which still beat the average analyst estimate of $3.88 per share, according to LSEG data. The results were "essentially in-linish ... although not anything significant for the Street given that it is still early in the year," David Song, portfolio manager of the Tema Obesity & Cardiometabolic ETF said in an email.

  • Investor's Business Daily

    Amgen Surges On Strong First-Quarter Profit As Obesity Space Heats Up

    Amgen stock popped late Thursday despite its profit beat as investors watch its potential rivals to Lilly and Novo drugs.